Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) Operating Income (2022 - 2025)

Bioregenx (BRGX) has 4 years of Operating Income data on record, last reported at -$8459.0 in Q3 2025.

  • For Q3 2025, Operating Income rose 97.42% year-over-year to -$8459.0; the TTM value through Sep 2025 reached -$18.6 million, down 299.84%, while the annual FY2024 figure was -$22.8 million, 567.78% down from the prior year.
  • Operating Income reached -$8459.0 in Q3 2025 per BRGX's latest filing, up from -$107259.0 in the prior quarter.
  • Across five years, Operating Income topped out at -$2191.0 in Q3 2022 and bottomed at -$18.3 million in Q4 2024.
  • Average Operating Income over 4 years is -$1.8 million, with a median of -$192615.0 recorded in 2025.
  • Peak YoY movement for Operating Income: plummeted 112567.91% in 2023, then surged 97.42% in 2025.
  • A 4-year view of Operating Income shows it stood at -$5535.0 in 2022, then crashed by 3722.13% to -$211555.0 in 2023, then plummeted by 8558.18% to -$18.3 million in 2024, then skyrocketed by 99.95% to -$8459.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$8459.0 in Q3 2025, -$107259.0 in Q2 2025, and -$192615.0 in Q1 2025.